Terkko Navigator / Lancet Infectious Diseases

A case of SARS-CoV-2 reinfection in Ecuador

Accurate, rapid, point-of-care tests for sexually transmitted infections

Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study

Correction to Lancet Infect Dis 2020; published online Oct 13. https://doi.org/10.1016/S1473-3099(20)30736-2

SARS-CoV-2 and the human-animal interface: outbreaks on mink farms

Ct values and infectivity of SARS-CoV-2 on surfaces

Kinetics and seroprevalence of SARS-CoV-2 antibodies in children

Expecting the unexpected with COVID-19 vaccines

Vaccine innovation spurred by the long wait for an Ebola virus vaccine

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9–50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study

Optimising dengue pre-vaccination screening

Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials

Hydroxychloroquine and COVID-19: a tale of populism and obscurantism

Welcoming science back at the White House

The search for an efficacious shigella vaccine

Polymyxins resistance among Gram-negative pathogens in India

Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study

Validating clinical practice guidelines for the management of children with non-blanching rashes in the UK (PiC): a prospective, multicentre cohort study

Vanishing evidence of the non-blanching rash?

Correction to Lancet Infect Dis 2020; published online Oct 19. https://doi.org/10.1016/S1473-3099(20)30769-6

Correction to Lancet Infect Dis 2020; published online Oct 12. https://doi.org/10.1016/S1473-3099(20)30783-0

Correction to Lancet Infect Dis 2020; published online Oct 29. https://doi.org/10.1016/S1473-3099(20)30592-2

Arthritogenic alphaviruses: epidemiological and clinical perspective on emerging arboviruses

SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study

Limitations of using mobile phone data to model COVID-19 transmission in the USA

Novel evidence to motivate onchocerciasis elimination

Evaluating case definitions for Ebola virus disease

Streptococcal toxic shock syndrome revealed phlegmasia cerulea dolens of the arm

Correction to Lancet Infect Dis 2020; published online Oct 5. https://doi.org/10.1016/S1473-3099(20)30480-1

Highly targeted spatiotemporal interventions against cholera epidemics, 2000–19: a scoping review

Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis

Correction to Lancet Infect Dis 2020; 20: e108–15

The scientific and ethical feasibility of immunity passports

A promising inactivated whole-virion SARS-CoV-2 vaccine

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Vertical transmission of Zika virus and its outcomes: a Bayesian synthesis of prospective studies

Desideratum: a developmentalist view of Zika virus infection

Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study

Immunity to Ebola virus: the full picture is being revealed

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 tr

Cefiderocol: the Trojan horse has arrived but will Troy fall?

Genomic evidence for reinfection with SARS-CoV-2: a case study

What reinfections mean for COVID-19

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Beyond COVID-19—a paradigm shift in infection management?

Catherine Wilfert

China's successful control of COVID-19

The intersection of COVID-19 and mental health